Skip to main content

Advertisement

Table 3 The demographic and comorbid medical disorders at index date after propensity score weighting among hypertensive and diabetic patients who were prescribed with either angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) stratified by chronic kidney disease or not

From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

  Propensity score weighting
With CKD Without CKD
ACEi (n = 932) ARB (n = 2135) Standardized mean difference ACEi (n = 5966) ARB (n = 10,623) Standardized mean difference
Duration from DM to index date (years) 3.50 ± 3.33 3.52 ± 2.09 −0.0049 3.00 ± 3.11 3.01 ± 2.29 −0.0035
Age (years) (mean ± SD) 65.5 ± 13.3 65.2 ± 8.8 0.0276 60.8 ± 12.9 60.6 ± 9.8 0.0175
Age group (years)    0.0123    0.0049
 20–49 (%) 14.70 15.06   21.81 21.92  
 50–64 (%) 32.08 32.25   40.56 40.69  
 65+ (%) 53.22 52.69   37.63 37.39  
Male sex 59.12 % 59.21 % −0.0019 59.52 % 59.62 % −0.0019
Congestive heart failure 8.05 % 8.15 % −0.0039 3.96 % 3.94 % 0.0006
Stroke 16.20 % 16.15 % 0.0014 12.19 % 12.16 % 0.0007
Malignant dysrhythmia 0.21 % 0.21 % 0.0014 0.49 % 0.48 % 0.0011
Cardiogenic shock 0.64 % 0.73 % −0.0102 0.27 % 0.27 % −0.0011
MI/PCI 5.15 % 5.08 % 0.0030 4.98 % 4.96 % 0.0008
CABG 0.11 % 0.11 % −0.0010 0.52 % 0.51 % 0.0008
Thrombolysis therapy 0.00 % 0.00 % −0.0002 0.28 % 0.28 % 0.0012
Hyperlipidemia 59.44 % 59.86 % −0.0085 53.77 % 53.77 % −0.0017
Incidence of ESRDa 1.39 2.34   0.30 0.37  
(95 % CI) (1.00−1.78) (1.80−2.89)   (0.23−0.37) (0.29−0.46)  
  1. DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CKD chronic kidney diseases, MI myocardial infarction, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery
  2. aIncidence per 100 person-years